IgA-driven neutrophil activation underlies post-Zika severe dengue disease in humans

Competing Interest Statement

EH laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine recipients. EH served on one-time advisory boards for Merck and Takeda. G.A. was an employee of Moderna Therapeutics and holds equity in Leyden Labs and Systems Seromyx. The other authors declare that they have no competing interests.

Funding Statement

This work was supported by NIH/NIAID grants P01AI106695 (EH) and U01AI153416 (EH). The Nicaraguan cohort and hospital studies were supported by NIH/NIAID grants U19AI118610 (EH), R01 AI099631 (AB), P01AI106695 (EH), and U01AI153416 (EH). MJRB is supported by funding from the Research Centers in Minority Institutions (RCMI) Center for Research Resources Grant and the Molecular and Genomics Core (U54MD007579) and the Hispanic Alliance for Clinical and Translational Research - Mentor Mentee Program Grant (5U54GM133807-03)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Pediatric Dengue Cohort Study was reviewed and approved by the institutional review boards of the University of California, Berkeley (protocol 2010-09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health (NIC-MINSA/CNDR CIRE-09/03/07-008). The Pediatric Dengue Hospital-based Study was reviewed and approved by the institutional review boards of the University of California, Berkeley (2010-06-1649) and the Nicaraguan Ministry of Health (NIC-MINSA/CNDR CIRE-01/10/06-13). Parents or legal guardians of all subjects provide written informed consent, and subjects ≥6 years old provide assent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes